Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of 5-Fluorouridine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY6 | Q15077 | 2/20 | 0.68 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.68 |
| ▸ | NT5E | P21589 | 1/20 | 0.68 |
| ▸ | PYGM | P11217 | 3/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.62 |
| ▸ | HBB | P68871 | 1/20 | 0.62 |
| ▸ | TK2 | O00142 | 2/20 | 0.60 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.57 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.56 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.55 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.55 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.55 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 5-Fluorouridine SCHEMBL148674 | 1.00 | P2RY6 (0.68) | P2RY6P2RY14NT5EPYGMLMNA | |
| 5-Fluorouridine SCHEMBL19901621 | 0.95 | PYGM (0.70) | P2RY6P2RY14NT5EPYGMLMNA | |
| 5-Fluorouridine SCHEMBL3385435 | 0.95 | PYGM (0.70) | P2RY6P2RY14NT5EPYGMLMNA | |
| 5-Fluorouridine SCHEMBL1682759 | 0.95 | PYGM (0.70) | P2RY6P2RY14NT5EPYGMLMNA | |
| 5-Fluorouridine SCHEMBL329381 | 0.95 | PYGM (0.70) | P2RY6P2RY14NT5EPYGMLMNA | |
| 5-Fluorouridine SCHEMBL12174049 | 0.95 | PYGM (0.70) | P2RY6P2RY14NT5EPYGMLMNA | |
| 5-Fluorouridine SCHEMBL11756887 | 0.95 | PYGM (0.70) | P2RY6P2RY14NT5EPYGMLMNA | |
| 5-Fluorouridine SCHEMBL17173362 | 0.95 | PYGM (0.70) | P2RY6P2RY14NT5EPYGMLMNA | |
| 5-Fluorouridine SCHEMBL21423048 | 0.95 | PYGM (0.70) | P2RY6P2RY14NT5EPYGMLMNA | |
| 5-Fluorouridine SCHEMBL214536 | 0.95 | PYGM (0.70) | P2RY6P2RY14NT5EPYGMLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021260322-A1 | STRAINS OF CLOSTRIDIUM BACTERIA RESISTANT TO 5-FLUOROURACIL, GENETIC TOOLS AND USES THEREOF | IFP Energies Nouvelles (FR) | 2021-12-30 | — | — | WO | claimed |
| EP-0791056-B1 | LIPID-CLEAVAGE ENZYME COMPLEX | HEIDELBERG PHARMA GMBH (DE) | 2005-03-30 | — | — | EP | claimed |
| US-20030082167-A1 | Lapid cleavage enzyme | HEIDELBERG PHARMA HOLDING GMBH | 2003-05-01 | — | — | US | claimed |
| US-20020106363-A1 | LIPID CLEAVAGE ENZYME | HEIDELBERG PHARMA HOLDING GMBH (DE) | 2002-08-08 | — | — | US | claimed |
| EP-0302473-B1 | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells | BRISTOL MYERS SQUIBB CO (US) | 1995-02-15 | — | — | EP | claimed |
| US-4975278-A | Converting the prodrug at the tumor site to the active drug by means of the conjugate bound to a tumor surface antigen | BRISTOL-MYERS COMPANY (US) | 1990-12-04 | — | — | US | claimed |
| EP-0302473-A2 | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells | Bristol-Myers Squibb Company (US) | 1989-02-08 | — | — | EP | claimed |
| EP-4696780-A1 | METHOD FOR TRANSFORMING BACTERIUM BELONGING TO GENUS BIFIDOBACTERIUM | Kabushiki Kaisha Yakult Honsha (JP) | 2026-02-18 | — | — | EP | disclosed |
| EP-4689128-A1 | NUCLEIC ACID MOLECULE AND METHODS | Forge Genetics Ltd (GB) | 2026-02-11 | — | — | EP | disclosed |
| EP-4689059-A1 | MODIFIED CLOSTRIDIUM BACTERIA, GENETIC EDITING TOOL FOR THE PSOL PLASMID OF CLOSTRIDIUM BACTERIA AND USES THEREOF | IFP Energies nouvelles (FR) | 2026-02-11 | — | — | EP | disclosed |
| US-12146135-B2 | Method for editing filamentous fungal genome through direct introduction of genome-editing protein | NATIONAL RESEARCH INSTITUTE OF BREWING (JP) | 2024-11-19 | — | — | US | disclosed |
| WO-2024209201-A1 | NUCLEIC ACID MOLECULE AND METHODS | THE UNIVERSITY OF NOTTINGHAM (GB) | 2024-10-10 | — | — | WO | disclosed |
| WO-2024200980-A1 | MODIFIED CLOSTRIDIUM BACTERIA, GENETIC EDITING TOOL FOR THE PSOL PLASMID OF CLOSTRIDIUM BACTERIA AND USES THEREOF | IFP Energies Nouvelles (FR) | 2024-10-03 | — | — | WO | disclosed |
| US-5859295-A | Canavanine analogs and their use as chemotherapeutic agents | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 1999-01-12 | — | — | US | disclosed |
| EP-0540859-B1 | Anthracycline prodrugs | BRISTOL MYERS SQUIBB CO (US) | 1998-01-14 | — | — | EP | disclosed |
| US-5552440-A | Use of L-canavanine as a chemotherapeutic agent for the treatment of pancreatic cancer | THE UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 1996-09-03 | — | — | US | disclosed |
| EP-0302473-B1 | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells | BRISTOL MYERS SQUIBB CO (US) | 1995-02-15 | — | — | EP | disclosed |
| EP-0540859-A1 | Anthracycline prodrugs | Bristol-Myers Squibb Company (US) | 1993-05-12 | — | — | EP | disclosed |
| US-4975278-A | Converting the prodrug at the tumor site to the active drug by means of the conjugate bound to a tumor surface antigen | BRISTOL-MYERS COMPANY (US) | 1990-12-04 | — | — | US | disclosed |
| EP-0302473-A2 | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells | Bristol-Myers Squibb Company (US) | 1989-02-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030082167-A1 | Lapid cleavage enzyme | LAP3, NAALAD2, ENGASE | P2RY6 3635/4885P2RY14 2861/4885NT5E 621/4885 |
| US-20020106363-A1 | LIPID CLEAVAGE ENZYME | SMPD1, MMEL1, ENGASE | P2RY6 3422/4885P2RY14 2684/4885NT5E 528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.